肿瘤治疗对睾丸癌患者生育预后的影响有限:系统回顾和荟萃分析。

IF 3.2 2区 医学 Q1 ANDROLOGY
Andrology Pub Date : 2024-08-27 DOI:10.1111/andr.13741
Janna Pape, Jancy Fernando, Dimitrios Megaritis, Susanna Weidlinger, Angela Vidal, Frédéric D Birkhäuser, Tanya Karrer, Michael von Wolff
{"title":"肿瘤治疗对睾丸癌患者生育预后的影响有限:系统回顾和荟萃分析。","authors":"Janna Pape, Jancy Fernando, Dimitrios Megaritis, Susanna Weidlinger, Angela Vidal, Frédéric D Birkhäuser, Tanya Karrer, Michael von Wolff","doi":"10.1111/andr.13741","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Testicular cancer is the most common solid tumour among young men in the reproductive phase. After completing cancer treatment, up to 77% of cancer survivors report an interest in paternity after completing cancer treatment. To preserve fertility, most guidelines recommend that physicians should counsel their patients about sperm cryopreservation before initiating gonadotoxic therapy. However, few studies have assessed fertility parameters after testicular cancer therapies over the last 20 years.</p><p><strong>Objectives: </strong>To close the gap of data regarding gonadotoxicity of testicular cancer therapies to enable more accurate counselling regarding fertility preservation.</p><p><strong>Materials and methods: </strong>A systematic literature search was conducted in Medline, Embase and Cochrane until December 2022. The systematic review included studies of men who had undergone all types of unilateral testicular cancer treatment, whereas the meta-analysis excluded studies with unspecified treatments, less than 10 patients for outcome evaluation or rare tumours. Infertility (i.e. azoospermia, failure to achieve paternity or the usage of cryosperm) was defined as outcome.</p><p><strong>Results: </strong>The qualitative analysis included 30 studies with a total of 13,718 men after unilateral testicular cancer. Treatment comprised active surveillance after unilateral orchidectomy (32.7%), radiotherapy (23.1%), standard- or low-dose chemotherapy (33.7%) and high-dose chemotherapy (1.4%). Post-treatment spermiograms were analysed in 17 studies. The quantitative synthesis included 23 studies, revealing an overall pooled prevalence of infertility (95% CI) of 14% (9%-21%). Azoospermia occurred in 8% (6%-12%). For good-prognosis patients who received standard therapy, the overall prevalence of infertility was only 4% (2%-10%).</p><p><strong>Conclusion: </strong>So far, this very first meta-analysis of overall infertility prevalence provides the best approximation of fertility prognosis for men who have undergone testicular cancer therapy. Despite the low prevalence of infertility, it is still recommended to undergo sperm cryopreservation because of the uncertainty of the subsequent therapy and the lack of large longitudinal data on individual treatment effects.</p>","PeriodicalId":7898,"journal":{"name":"Andrology","volume":" ","pages":""},"PeriodicalIF":3.2000,"publicationDate":"2024-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Oncological treatments have limited effects on the fertility prognosis in testicular cancer: A systematic review and meta-analysis.\",\"authors\":\"Janna Pape, Jancy Fernando, Dimitrios Megaritis, Susanna Weidlinger, Angela Vidal, Frédéric D Birkhäuser, Tanya Karrer, Michael von Wolff\",\"doi\":\"10.1111/andr.13741\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Testicular cancer is the most common solid tumour among young men in the reproductive phase. After completing cancer treatment, up to 77% of cancer survivors report an interest in paternity after completing cancer treatment. To preserve fertility, most guidelines recommend that physicians should counsel their patients about sperm cryopreservation before initiating gonadotoxic therapy. However, few studies have assessed fertility parameters after testicular cancer therapies over the last 20 years.</p><p><strong>Objectives: </strong>To close the gap of data regarding gonadotoxicity of testicular cancer therapies to enable more accurate counselling regarding fertility preservation.</p><p><strong>Materials and methods: </strong>A systematic literature search was conducted in Medline, Embase and Cochrane until December 2022. The systematic review included studies of men who had undergone all types of unilateral testicular cancer treatment, whereas the meta-analysis excluded studies with unspecified treatments, less than 10 patients for outcome evaluation or rare tumours. Infertility (i.e. azoospermia, failure to achieve paternity or the usage of cryosperm) was defined as outcome.</p><p><strong>Results: </strong>The qualitative analysis included 30 studies with a total of 13,718 men after unilateral testicular cancer. Treatment comprised active surveillance after unilateral orchidectomy (32.7%), radiotherapy (23.1%), standard- or low-dose chemotherapy (33.7%) and high-dose chemotherapy (1.4%). Post-treatment spermiograms were analysed in 17 studies. The quantitative synthesis included 23 studies, revealing an overall pooled prevalence of infertility (95% CI) of 14% (9%-21%). Azoospermia occurred in 8% (6%-12%). For good-prognosis patients who received standard therapy, the overall prevalence of infertility was only 4% (2%-10%).</p><p><strong>Conclusion: </strong>So far, this very first meta-analysis of overall infertility prevalence provides the best approximation of fertility prognosis for men who have undergone testicular cancer therapy. Despite the low prevalence of infertility, it is still recommended to undergo sperm cryopreservation because of the uncertainty of the subsequent therapy and the lack of large longitudinal data on individual treatment effects.</p>\",\"PeriodicalId\":7898,\"journal\":{\"name\":\"Andrology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.2000,\"publicationDate\":\"2024-08-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Andrology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1111/andr.13741\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ANDROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Andrology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/andr.13741","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ANDROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:睾丸癌是处于生育期的年轻男性最常见的实体肿瘤。在完成癌症治疗后,高达 77% 的癌症幸存者表示有兴趣成为父亲。为了保护生育能力,大多数指南都建议医生在开始性腺毒性治疗前,应向患者提供精子冷冻保存方面的咨询。然而,在过去20年中,很少有研究对睾丸癌治疗后的生育能力参数进行评估:弥补睾丸癌疗法的性腺毒性方面的数据缺口,以便为患者提供更准确的生育力保存建议:在Medline、Embase和Cochrane中进行了系统性文献检索,直至2022年12月。系统综述包括对接受过所有类型单侧睾丸癌治疗的男性进行的研究,而荟萃分析则排除了治疗方法不明确、结果评估患者少于 10 人或罕见肿瘤的研究。不育(即无精子症、无法取得父子关系或使用冷冻精子)被定义为结果:定性分析包括30项研究,共有13718名男性接受了单侧睾丸癌治疗。治疗包括单侧睾丸切除术后的积极监测(32.7%)、放疗(23.1%)、标准或低剂量化疗(33.7%)和高剂量化疗(1.4%)。17项研究对治疗后的精子图进行了分析。定量综述包括 23 项研究,汇总后的不育症发病率(95% CI)为 14% (9%-21%)。无精子症发生率为 8%(6%-12%)。对于接受标准治疗的预后良好的患者,不育症的总发生率仅为4%(2%-10%):到目前为止,这项首次关于不育症总体发生率的荟萃分析为接受睾丸癌治疗的男性提供了最佳的生育预后近似值。尽管不育症的发生率较低,但由于后续治疗的不确定性以及缺乏关于个体治疗效果的大量纵向数据,因此仍建议进行精子冷冻保存。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Oncological treatments have limited effects on the fertility prognosis in testicular cancer: A systematic review and meta-analysis.

Background: Testicular cancer is the most common solid tumour among young men in the reproductive phase. After completing cancer treatment, up to 77% of cancer survivors report an interest in paternity after completing cancer treatment. To preserve fertility, most guidelines recommend that physicians should counsel their patients about sperm cryopreservation before initiating gonadotoxic therapy. However, few studies have assessed fertility parameters after testicular cancer therapies over the last 20 years.

Objectives: To close the gap of data regarding gonadotoxicity of testicular cancer therapies to enable more accurate counselling regarding fertility preservation.

Materials and methods: A systematic literature search was conducted in Medline, Embase and Cochrane until December 2022. The systematic review included studies of men who had undergone all types of unilateral testicular cancer treatment, whereas the meta-analysis excluded studies with unspecified treatments, less than 10 patients for outcome evaluation or rare tumours. Infertility (i.e. azoospermia, failure to achieve paternity or the usage of cryosperm) was defined as outcome.

Results: The qualitative analysis included 30 studies with a total of 13,718 men after unilateral testicular cancer. Treatment comprised active surveillance after unilateral orchidectomy (32.7%), radiotherapy (23.1%), standard- or low-dose chemotherapy (33.7%) and high-dose chemotherapy (1.4%). Post-treatment spermiograms were analysed in 17 studies. The quantitative synthesis included 23 studies, revealing an overall pooled prevalence of infertility (95% CI) of 14% (9%-21%). Azoospermia occurred in 8% (6%-12%). For good-prognosis patients who received standard therapy, the overall prevalence of infertility was only 4% (2%-10%).

Conclusion: So far, this very first meta-analysis of overall infertility prevalence provides the best approximation of fertility prognosis for men who have undergone testicular cancer therapy. Despite the low prevalence of infertility, it is still recommended to undergo sperm cryopreservation because of the uncertainty of the subsequent therapy and the lack of large longitudinal data on individual treatment effects.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Andrology
Andrology ANDROLOGY-
CiteScore
9.10
自引率
6.70%
发文量
200
期刊介绍: Andrology is the study of the male reproductive system and other male gender related health issues. Andrology deals with basic and clinical aspects of the male reproductive system (gonads, endocrine and accessory organs) in all species, including the diagnosis and treatment of medical problems associated with sexual development, infertility, sexual dysfunction, sex hormone action and other urological problems. In medicine, Andrology as a specialty is a recent development, as it had previously been considered a subspecialty of urology or endocrinology
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信